Personalized medicine in multiple sclerosis: hope or reality?

BMC Medicine

Minireview

Tobias Derfuss¹ 

[1] Department of Neurology, University Hospital Basel, 4031, Petersgraben 4, Basel, Switzerland;Department of Biomedicine, University Hospital Basel, 4031, Hebelstrasse 20, Basel, Switzerland;

关键词: biomarker;    multiple sclerosis;    personalized medicine;   

DOI  :  10.1186/1741-7015-10-116

 received in 2012-07-25, accepted in 2012-10-04,  发布年份 2012

来源: Springer

【 摘 要 】

Personalized treatment is highly desirable in multiple sclerosis because it is an immensely heterogeneous disease. This heterogeneity is seen in both the disease course and the treatment responses. Currently, a combination of clinical features and imaging parameters in magnetic resonance imaging is used to classify active and non-active patients and treatment responders and non-responders. Although this classification works on a group level, individual patients often behave differently from the group. Therefore additional biomarkers are needed to provide better indicators for prognosis and treatment response. Basic and clinical research have discovered different promising targets. It is now essential to verify the utility and accuracy of these markers in large, prospectively sampled patient cohorts.

【 授权许可】

CC BY   
© Derfuss; licensee BioMed Central Ltd. 2012